Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Legend Biotech Corp ADR (NQ: LEGN )

40.94 +1.19 (+2.99%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corp ADR

< Previous 1 2 3 4 5 6 7 8 9 Next >
Assessing Legend Biotech: Insights From 15 Financial Analysts
Via Benzinga
Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst
Legend Biotech analyst predicts growth for Carvykti. The Multiple Myeloma drug could become a $5B+ product. 
Via Benzinga
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts. 
Via Benzinga
Unveiling 18 Analyst Insights On Legend Biotech
Via Benzinga
Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
From Legend Biotech
Via Business Wire
Legend Biotech to Participate in the Jefferies Global Healthcare Conference
From Legend Biotech Corporation
Via Business Wire
Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
From Legend Biotech Corporation
Via Business Wire
Legend Biotech Stock: A Deep Dive Into Analyst Perspectives (14 Ratings)
Via Benzinga
Amid Biotech Pitfalls, ImmunityBio Has Outperformed NVDA In The Last 3 Months
In the last three months, IBRX outperformed NVDA by over 3x. 
Via Talk Markets
LEGN Stock Earnings: Legend Biotech Beats EPS, Misses Revenue for Q1 2024
LEGN stock results show that Legend Biotech beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Analyst Ratings For Legend Biotech
Via Benzinga
Unveiling 9 Analyst Insights On Legend Biotech
Via Benzinga
Earnings Preview: Legend Biotech
Via Benzinga
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
From Legend Biotech Corporation
Via Business Wire
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
From Legend Biotech Corporation
Via Business Wire
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel 
Via Benzinga
Exposures Product Safety
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
From Legend Biotech Corporation
Via Business Wire
What 4 Analyst Ratings Have To Say About Legend Biotech
Via Benzinga
Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population
FDA approves Johnson & Johnson's Carvykti, a BCMA-targeted therapy for relapsed or refractory multiple myeloma patients, offering hope with increased manufacturing capacity and extended collaboration... 
Via Benzinga
Exposures Product Safety
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
From Legend Biotech Corporation
Via Business Wire
GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy
Key Takeaways: GenScript’s cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary gained traction Legend’s Carvykti is expected to hit annual... 
Via Benzinga
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
From Legend Biotech Corporation
Via Business Wire
FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer
FDA's adcomm recommends expanded use of Bristol Myers Squibb's Abecma for triple-class exposed relapsed or refractory multiple myeloma, based on Phase 3 study results. Positive vote for Johnson &... 
Via Benzinga
Exposures Product Safety
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
From Legend Biotech Corporation
Via Business Wire
FDA To Review Two Cell Therapies For Multiple Myeloma This Week - Johnson & Johnson And Bristol-Myers
Join the FDA's Oncologic Drugs Advisory Committee on March 15th to review Johnson & Johnson/Legend Biotech's Carvykti application for relapsed/refractory multiple myeloma treatment. Delve into... 
Via Benzinga
Exposures Product Safety
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday. 
Via Benzinga
Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
From Legend Biotech Corporation
Via Business Wire
Earnings Scheduled For March 11, 2024
Companies Reporting Before The Bell • Ballard Power Systems (NASDAQ:BLDP) is estimated to report quarterly loss at $0.13 per share on revenue of $34.20 million. 
Via Benzinga
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the... 
Via Talk Markets
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.